Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Capital Expenditures (2016 - 2023)

Sonoma Pharmaceuticals (SNOA) has 4 years of Capital Expenditures data on record, last reported at $129000.0 in Q1 2013.

  • For Q1 2013, Capital Expenditures fell 50.0% year-over-year to $129000.0; the TTM value through Mar 2013 reached $257000.0, down 23.51%, while the annual FY2025 figure was $80000.0, 3900.0% up from the prior year.
  • Capital Expenditures reached $129000.0 in Q1 2013 per SNOA's latest filing, up from $66000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $258000.0 in Q1 2012 and bottomed at -$24000.0 in Q4 2011.
  • Average Capital Expenditures over 4 years is $55083.3, with a median of $42500.0 recorded in 2010.
  • Peak YoY movement for Capital Expenditures: tumbled 340.0% in 2011, then skyrocketed 5260.0% in 2012.
  • A 4-year view of Capital Expenditures shows it stood at $10000.0 in 2010, then crashed by 340.0% to -$24000.0 in 2011, then soared by 375.0% to $66000.0 in 2012, then surged by 95.45% to $129000.0 in 2013.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $129000.0 in Q1 2013, $66000.0 in Q4 2012, and $60000.0 in Q3 2012.